P

PopVax Tech Stack

mRNA vaccine platform using computational protein design

Biotechnology Research Hyderabad 51–200 employees Founded 2021 Privately Held

PopVax is a full-stack mRNA vaccine biotech founded in 2021, running a Phase I clinical trial for a next-generation COVID-19 booster and developing tuberculosis vaccines through computational protein design. The hiring mix is heavily research-focused (17 of 29 active roles) with emerging data and engineering functions, suggesting a company scaling from bench discovery toward manufacturing and regulatory validation. Current pain points center on GMP production operationalization, clinical program velocity, and supply chain friction—typical of a preclinical biotech ramping toward commercialization.

Tech Stack 10 technologies

Core StackPython GraphPad Prism FlowJo Prism R HPLC UHPLC UPLC LC-MS CAD

What PopVax Is Building

◆Challenges

Accelerating drug development
Complex r&d program execution
Fast-moving clinical program management
Scaling production capacity
Adapting cutting-edge technologies to cgmp production
Operationalising gmp-capable mrna foundry
Sourcing gmp-grade materials
Import customs clearance
Managing growing patent portfolio
Defining ip strategy

▲Active Projects

Phase i clinical trial of first vaccine program
Mtb vaccine development
Phase i clinical trials for novel vaccines
Stable cell line generation
Adme studies for mrna candidates
Covid-19 booster phase i trial
Mrna ivt
Mab production
Gene expression workflows
Flow cytometry-based t-cell assay validation

Hiring Activity

Minimal30 roles · 0 in 30d

Department

Research

17

Manufacturing

3

Legal

2

Data

1

Engineering

1

Executive

1

HR

1

Marketing

1

Seniority

Mid

9

Senior

6

Junior

5

Principal

4

Manager

3

C-Level

1

VP

1

Notable leadership hires: Chief Regulatory Officer

Company intelligence

Find more companies like PopVax by tech stack, pain points and active projects

Get started free

About PopVax

PopVax develops novel mRNA vaccines and therapeutics using computational protein design methods. The company operates a fully integrated R&D and GMP-capable clinical dose manufacturing facility (RNA Foundry) in Hyderabad, India. The lead program is a SARS-CoV-2 booster vaccine designed to broaden coverage against current and predicted variants; a Phase I trial in the U.S. is planned to launch in the near term. Secondary programs include tuberculosis vaccine development. PopVax is funded primarily through project agreements with the Bill & Melinda Gates Foundation and a biosecurity organization. The company employs 70+ staff across computational design, machine learning, molecular and cell biology, immunology, mRNA delivery, analytical chemistry, GMP production, quality, and regulatory functions.

HeadquartersHyderabad

Company Size51–200 employees

Founded2021

Hiring MarketsIndia

Frequently Asked Questions

What is PopVax's lead vaccine program?

A next-generation COVID-19 booster vaccine designed to protect against current and predicted future SARS-CoV-2 variants. Phase I clinical trials in the U.S. are planned to initiate in the near term.

Where is PopVax headquartered and what is the RNA Foundry?

PopVax is headquartered in Hyderabad, India. The RNA Foundry is the company's integrated R&D and GMP-capable clinical manufacturing facility, also located in Hyderabad.